Z. Chen, C. Fillmore, P. Hammerman, C. Kim, and K. Wong, Non-small-cell lung cancers: a heterogeneous set of diseases, Nature Reviews Cancer, vol.8, issue.8, pp.535-546, 2014.
DOI : 10.1038/nrc3775

G. Bronte, C. Rolfo, E. Giovannetti, G. Cicero, P. Pauwels et al., Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects, Critical Reviews in Oncology/Hematology, vol.89, issue.2, pp.300-313, 2014.
DOI : 10.1016/j.critrevonc.2013.08.003

B. Solomon, K. Wilner, and A. Shaw, Current Status of Targeted Therapy for Anaplastic Lymphoma Kinase???Rearranged Non???Small Cell Lung Cancer, Clinical Pharmacology & Therapeutics, vol.23, issue.1, pp.15-23, 2014.
DOI : 10.1158/1078-0432.CCR-12-3381

D. Camidge, Y. Bang, E. Kwak, A. Iafrate, M. Varella-garcia et al., Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, The Lancet Oncology, vol.13, issue.10, pp.1011-1019, 2012.
DOI : 10.1016/S1470-2045(12)70344-3

A. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-2394, 2013.
DOI : 10.1056/NEJMoa1214886
URL : https://hal.archives-ouvertes.fr/in2p3-00459276

C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu et al., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, The Lancet Oncology, vol.12, issue.8, pp.735-742, 2011.
DOI : 10.1016/S1470-2045(11)70184-X

D. Abreu, G. Lopez-vivanco, V. Gebbia, L. Ferrera-delgado, P. Bombaron et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-246, 2012.

M. , Y. H. Kinoshita, I. Fujita, Y. Okinaga, S. Hirano et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, vol.362, pp.2380-2388, 2010.

T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncology, vol.11, issue.2, 2010.
DOI : 10.1016/S1470-2045(09)70364-X

C. Gridelli, D. Marinis, F. , D. Maio, M. Cortinovis et al., Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence, Lung Cancer, vol.71, issue.3, pp.249-257, 2011.
DOI : 10.1016/j.lungcan.2010.12.008

H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, vol.448, pp.561-566, 2007.

N. Lindeman, P. Cagle, M. Beasley, D. Chitale, S. Dacic et al., Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors, The Journal of Molecular Diagnostics, vol.15, issue.4, pp.415-453, 2013.
DOI : 10.1016/j.jmoldx.2013.03.001

M. Soda, K. Isobe, A. Inoue, M. Maemondo, S. Oizumi et al., A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.18, issue.20, pp.5682-5689, 2012.
DOI : 10.1158/1078-0432.CCR-11-2947

K. Gruber, H. Horn, J. Kalla, P. Fritz, A. Rosenwald et al., Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription Polymerase Chain Reaction Assay, Journal of Thoracic Oncology, vol.9, issue.3, pp.307-315, 2014.
DOI : 10.1097/JTO.0000000000000068

K. Zwaenepoel, A. Van-dongen, S. Lambin, C. Weyn, and P. Pauwels, gene rearrangements - comparison of multiple immunohistochemical methods, Histopathology, vol.13, issue.4, pp.539-548, 2014.
DOI : 10.1111/his.12414

J. Merlio and M. Belaud-rotureau, Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances, J Thorac Oncol, vol.9, pp.295-306, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01064002

M. Laffert, A. Warth, R. Penzel, P. Schirmacher, D. Jonigk et al., Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing, Lung Cancer, vol.81, issue.2, pp.200-206, 2013.
DOI : 10.1016/j.lungcan.2013.04.015

K. Wu, R. Huang, L. House, and W. Cho, Next-generation sequencing for lung cancer, Future Oncology, vol.9, issue.9, 2013.
DOI : 10.2217/fon.13.102

H. Abel, H. Kateb, C. Cottrell, A. Bredemeyer, C. Pritchard et al., Detection of Gene Rearrangements in Targeted Clinical Next-Generation Sequencing, The Journal of Molecular Diagnostics, vol.16, issue.4, pp.405-417, 2014.
DOI : 10.1016/j.jmoldx.2014.03.006

W. Olszewski, P. Pauwels, F. Penault-llorca, and G. Rossi, EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch, pp.245-257, 2012.

L. Tembuyser, V. Tack, K. Zwaenepoel, P. Pauwels, K. Miller et al., The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization, PLoS ONE, vol.16, issue.11, p.112159, 2014.
DOI : 10.1371/journal.pone.0112159.t008